Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mild to Moderate COVID-19 Clear all
Completed Phase 2 Interventional Results available

Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients

NCT04523181
View directory record Official record
Conditions
Covid-19
Interventions
Antroquinonol, Placebo
Drug · Other
Lead sponsor
Golden Biotechnology Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Michigan City, Indiana • Wichita, Kansas • Rockville, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Not applicable Interventional

A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function

NCT04486482
View directory record Official record
Conditions
Mild-to-Moderate COVID-19
Interventions
KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone
Other
Lead sponsor
Kaleido Biosciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
12
States / cities
Cullman, Alabama • Los Angeles, California • Rancho Cucamonga, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Jul 23, 2026, 5:22 AM EDT
Withdrawn Phase 1 Interventional

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

NCT05596045
View directory record Official record
Conditions
SARS CoV 2 Infection
Interventions
ASC10, Placebo
Drug
Lead sponsor
Ascletis Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Anniston, Alabama • Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients

NCT04524663
View directory record Official record
Conditions
Covid19
Interventions
Camostat Mesilate, Placebo, Standard of Care Treatment
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

NCT04402060
View directory record Official record
Conditions
COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome
Interventions
APL-9, Vehicle Control
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

NCT04551911
View directory record Official record
Conditions
COVID-19, Coronavirus, SARS-CoV2 Infection
Interventions
Rayaldee, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced Jul 23, 2026, 5:22 AM EDT
Completed No phase listed Observational Results available

A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

NCT07072793
View directory record Official record
Conditions
COVID-19 (Coronavirus Disease 2019)
Interventions
nirmatrelvir-ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
131,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 23, 2026, 5:22 AM EDT
Terminated Phase 3 Interventional Results available

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

NCT04913675
View directory record Official record
Conditions
Covid19
Interventions
Sotrovimab
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
12 Years and older
Enrollment
1,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Anniston, Alabama • Mesa, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

NCT04427501
View directory record Official record
Conditions
COVID-19
Interventions
LY3819253, LY3832479, LY3853113, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
0 Years and older
Enrollment
3,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Redondo Beach, California • Miami, Florida • Union City, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

NCT04343651
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Placebo, Leronlimab (700mg)
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Los Angeles, California • Palm Springs, California • Rancho Mirage, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

NCT04486313
View directory record Official record
Conditions
COVID-19
Interventions
Nitazoxanide, Placebo, Vitamin Super B-Complex
Drug · Dietary Supplement
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
12 Years to 120 Years
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Fort Lauderdale, Florida • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Jul 23, 2026, 5:22 AM EDT
Terminated Phase 1 Interventional

IMM-BCP-01 in Mild to Moderate COVID-19

NCT05429021
View directory record Official record
Conditions
SARS-CoV2 Infection, COVID-19
Interventions
IMM-BCP-01, Placebo
Drug
Lead sponsor
Immunome, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Long Beach, California • Miami Lakes, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Niclosamide for Mild to Moderate COVID-19

NCT04399356
View directory record Official record
Conditions
COVID-19
Interventions
Niclosamide, Placebo, Telehealth monitoring
Drug · Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Jul 23, 2026, 5:22 AM EDT
Withdrawn Phase 2 Interventional

iNOPulse for COVID-19

NCT04398290
View directory record Official record
Conditions
COVID-19, Hypoxemia, Hypoxemic Respiratory Failure
Interventions
Inhaled nitric oxide (iNO), Nitrogen gas, Oxygen gas
Drug
Lead sponsor
Roger Alvarez
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Tafenoquine in Patients With Mild to Moderate COVID-19

NCT04533347
View directory record Official record
Conditions
COVID 19 Disease
Interventions
Tafenoquine Oral Tablet, Placebo
Drug
Lead sponsor
60 Degrees Pharmaceuticals LLC
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Miami, Florida • Elkhorn, Nebraska • Morgantown, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

The Prevent Severe COVID-19 (PRESECO) Study

NCT04600895
View directory record Official record
Conditions
Covid19
Interventions
Favipiravir, Placebo
Drug
Lead sponsor
Appili Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Pelham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Not applicable Interventional

A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19

NCT04414124
View directory record Official record
Conditions
Mild-to-moderate COVID-19
Interventions
KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone
Other
Lead sponsor
Kaleido Biosciences
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Hot Springs, Arkansas • Riverside, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19

NCT05164120
View directory record Official record
Conditions
COVID-19
Interventions
Belnacasan, Placebo
Drug
Lead sponsor
MedStar Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

NCT05616728
View directory record Official record
Conditions
COVID-19
Interventions
EDP-235, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
22
States / cities
Lomita, California • Los Angeles, California • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Jul 23, 2026, 5:22 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

NCT04822701
View directory record Official record
Conditions
COVID-19
Interventions
BI 767551 intravenous, BI 767551 inhaled, Placebo intravenous, Placebo inhaled
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Miami Springs, Florida • Amarillo, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Jul 23, 2026, 5:22 AM EDT